BioMS autoimmune news

BioMS restructured and reduced headcount by 50% to reduce expenses. Director of Finance Brent Johnston will replace CFO Don Kimak, who will depart. BioMS, which had 30 employees and contract personnel at year end 2008, did not disclose its headcount following the restructuring.

The biotech also said it will discontinue development of dirucotide to treat multiple sclerosis after reviewing data from the compound's Phase III trials, including the MAESTRO-01 trial in which the synthetic myelin basic protein missed the primary endpoint of delayed disease progression (see BioCentury, Aug. 3, 2009 & Oct. 5, 2009). ...